Welcome to our dedicated page for Cartesian news (Ticker: RNAC), a resource for investors and traders seeking the latest updates and insights on Cartesian stock.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a clinical-stage biotechnology company that describes itself as pioneering cell therapy for autoimmune diseases. Its news flow centers on the development of its lead CAR-T candidate, Descartes-08, and its next-generation CAR-T program, Descartes-15. Company press releases highlight clinical trial milestones, regulatory designations, financial updates and corporate governance changes that are relevant for followers of RNAC news.
A major focus of Cartesian’s news is the Phase 3 AURORA trial of Descartes-08 in generalized myasthenia gravis (MG). Updates describe enrollment progress, prior Phase 2b data in MG, and the outpatient, no-preconditioning chemotherapy design of the AURORA trial. Additional news covers Descartes-08 development in systemic lupus erythematosus (SLE), including initial Phase 2 data, and the planned and ongoing expansion into myositis through a randomized, double-blind, placebo-controlled Phase 2 trial using a seamless adaptive design.
Cartesian also issues releases on pediatric autoimmune programs, such as a planned Phase 2 pediatric basket trial and the Phase 1/2 HELIOS pediatric trial, building on Rare Pediatric Disease Designation for Descartes-08 in juvenile dermatomyositis. Other recurring RNAC news items include quarterly financial results with commentary on cash runway and research and development spending, employment inducement grants under its inducement plan, and board and executive changes documented in Form 8-K filings, such as the appointment of new directors and officers.
Investors and observers tracking RNAC news can expect coverage of clinical data readouts, trial initiations or pauses, regulatory designations, strategic prioritization of indications, and corporate governance developments. Bookmarking this page provides a centralized view of Cartesian’s press releases and related updates as the company advances Descartes-08 and Descartes-15 through clinical development in autoimmune disease and multiple myeloma.
Cartesian Therapeutics announced positive results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). The trial met its primary endpoint, with 71% of treated patients showing significant improvement in MGC scores at Month 3 compared to 25% for placebo. Deep, durable responses were observed for at least six months. Descartes-08 was well tolerated, with mild and transient adverse events. The company plans to hold an End-of-Phase 2 meeting with the FDA by year-end. A conference call to discuss these results is scheduled for today at 8:00 a.m. ET. Cartesian also initiated a Phase 2 trial of Descartes-08 for systemic lupus erythematosus (SLE) and announced the appointment of Kemal Malik to its Board of Directors.
Cartesian Therapeutics (NASDAQ: RNAC) announced the issuance of an inducement award to a new employee. On June 3, 2024, the employee received an option to purchase 11,000 shares of the company's common stock at an exercise price of $36.00 per share, the closing trading price on the Nasdaq Global Market on the grant date.
The option is part of the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan, approved by the board. It vests 25% on June 3, 2025, with additional equal annual installments thereafter, fully vesting by June 3, 2028. The option has a ten-year term and was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules.
Cartesian Therapeutics announced that its lead product candidate, Descartes-08, has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for treating myasthenia gravis (MG). This designation, part of the 21st Century Cures Act, accelerates drug development for serious conditions. Descartes-08, an autologous mRNA CAR-T therapy targeting BCMA, showed promising results in a Phase 2a study, with no severe side effects and significant improvements in MG severity. The company is on track to release topline data from a Phase 2b trial by mid-2024.
Cartesian Therapeutics (NASDAQ:RNAC), a clinical-stage biotech company specializing in mRNA cell therapy for autoimmune diseases, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event, scheduled for May 20, 2024, at 3:00 p.m. ET, will feature a live fireside chat with the company’s management team. The webcast will be available on the company's website for a time.
Cartesian Therapeutics reported its first-quarter 2024 financial results, highlighting progress in its pipeline of mRNA cell therapy product candidates. The company remains on track to report topline data from the Phase 2b trial of Descartes-08 for myasthenia gravis by mid-2024. The new headquarters in Frederick, Maryland, is expected to support the company's manufacturing capabilities. With approximately $104.8 million in cash, cash equivalents, and restricted cash as of March 31, 2024, Cartesian is well-positioned to support its operations into the second half of 2026.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) granted inducement awards to four new employees by issuing options to purchase shares of the Company's common stock. The options have an exercise price of $22.64 and are exercisable for a total of 72,769 shares. Each option vests over time and has a ten-year term. The grants were made under the Company's 2018 Employment Inducement Incentive Award Plan and were approved by the board of directors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.